Literature DB >> 24283362

High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells.

Yi-Shing Ma1, I-Ping Yang, Hsiang-Lin Tsai, Ching-Wen Huang, Suh-Hang Hank Juo, Jaw-Yuan Wang.   

Abstract

5-Fluorouracil (5-FU)-based chemotherapy is widely used for the treatment of colorectal cancer (CRC). While optimal doses of 5-FU are generally established based on a patient's estimated body surface area, the plasma concentrations of 5-FU vary among patients. In addition, hyperglycemia in patients with CRC has been reported as a risk factor in poor prognosis. The aim of the present study was to investigate whether hyperglycemia affects antiproliferative effect of 5-FU on the human colon cancer cells (SW480, SW620, LoVo, and HCT116). Growth inhibition of 5-FU was accessed by WST-8 assay. The effect of high glucose (HG, 15 mM) and 5-FU on the cellular proliferation was evaluated by flow cytometry analysis using 5-ethynyl-2'-deoxy-uridine (EdU) incorporation plus 7-AAD. Cell death was determined by flow cytometry using Annexin V-FITC and PI. The results showed that HG, compared to physiological normal glucose (NG) concentration (5 mM), leads to increased cell proliferation and increased GI50 of 5-FU in the four colon cancer cell lines. When the cells were pretreated with a low-dose 5-FU in NG condition, subsequent HG treatment eliminated inhibitory effect of 5-FU in cancer cell growth. In the presence of 5-FU (0.5 μg/mL for LoVo and HCT116; 1 μg/mL for SW480 and SW620), culture with HG for 72 h does not significantly altered cell cycle profile in the four cell lines but significantly increased DNA replication in SW620 (21%) and LoVo (17%). Flow cytometric analysis showed that HG protects cells against 5-FU-induced cell death in SW480. Finally, HG did not alter intracellular level of reactive oxygen species (ROS), although 5-FU indeed induced higher intracellular level of ROS. In conclusion, HG attenuates growth inhibition of 5-FU and our results indicate that decreased cell death and increased DNA replication may account for the attenuating effect of a HG environment on 5-FU-induced tumor growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24283362      PMCID: PMC3929122          DOI: 10.1089/dna.2013.2161

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  42 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

Authors:  Rodrigo Jover; Thuy-Phuong Nguyen; Lucía Pérez-Carbonell; Pedro Zapater; Artemio Payá; Cristina Alenda; Estefanía Rojas; Joaquín Cubiella; Francesc Balaguer; Juan D Morillas; Juan Clofent; Luis Bujanda; Josep M Reñé; Xavier Bessa; Rosa M Xicola; David Nicolás-Pérez; Antoni Castells; Montserrat Andreu; Xavier Llor; C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-12-24       Impact factor: 22.682

Review 3.  Apoptosis and beyond: cytometry in studies of programmed cell death.

Authors:  Donald Wlodkowic; William Telford; Joanna Skommer; Zbigniew Darzynkiewicz
Journal:  Methods Cell Biol       Date:  2011       Impact factor: 1.441

4.  Polyamine metabolism in primary human colon adenocarcinoma cells (SW480) and their lymph node metastatic derivatives (SW620).

Authors:  B Duranton; V Holl; Y Schneider; S Carnesecchi; F Gossé; F Raul; N Seiler
Journal:  Amino Acids       Date:  2003       Impact factor: 3.520

5.  5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro.

Authors:  Jianfeng Zhou; Yanping Zhou; Bin Yin; Wei Hao; Lin Zhao; Wenyi Ju; Chunmei Bai
Journal:  Oncol Rep       Date:  2010-01       Impact factor: 3.906

6.  The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.

Authors:  Long-Hao Li; Hang Dong; Feng Zhao; Jie Tang; Xin Chen; Jing Ding; Hai-Tao Men; Wu-Xia Luo; Yang Du; Jun Ge; Ben-Xu Tan; Dan Cao; Ji-Yan Liu
Journal:  Eur J Cancer       Date:  2013-01-11       Impact factor: 9.162

Review 7.  Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis.

Authors:  Kelly B Stein; Claire F Snyder; Bethany B Barone; Hsin-Chieh Yeh; Kimberly S Peairs; Rachel L Derr; Antonio C Wolff; Frederick L Brancati
Journal:  Dig Dis Sci       Date:  2010-07       Impact factor: 3.199

8.  Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas.

Authors:  Andrew Flood; Volker Mai; Ruth Pfeiffer; Lisa Kahle; Alan T Remaley; Elaine Lanza; Arthur Schatzkin
Journal:  Gastroenterology       Date:  2007-08-21       Impact factor: 22.682

9.  Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer.

Authors:  Brian M Wolpin; Jeffrey A Meyerhardt; Andrew T Chan; Kimmie Ng; Jennifer A Chan; Kana Wu; Michael N Pollak; Edward L Giovannucci; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

Review 10.  The extracellular matrix: a dynamic niche in cancer progression.

Authors:  Pengfei Lu; Valerie M Weaver; Zena Werb
Journal:  J Cell Biol       Date:  2012-02-20       Impact factor: 10.539

View more
  22 in total

1.  NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells.

Authors:  Charupong Saengboonmee; Chatchai Phoomak; Suangson Supabphol; Kyle R Covington; Oliver Hampton; Chaisiri Wongkham; Richard A Gibbs; Kazuo Umezawa; Wunchana Seubwai; Marie-Claude Gingras; Sopit Wongkham
Journal:  Life Sci       Date:  2020-10-07       Impact factor: 5.037

Review 2.  Pathophysiological mechanisms of death resistance in colorectal carcinoma.

Authors:  Ching-Ying Huang; Linda Chia-Hui Yu
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

3.  Comprehensive transcriptome analysis of colorectal cancer risk of hyperglycemia in humans.

Authors:  Wenming Feng; Huihui Guo; Hui Gong; Tao Xue; Xiang Wang; Chengwu Tang; Yongqiang Xu; Chuang Dai; Ying Bao; Ting Zhang; Ge Cui
Journal:  J Gastrointest Oncol       Date:  2021-04

4.  High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity.

Authors:  Alessia Garufi; Gabriella D'Orazi
Journal:  J Exp Clin Cancer Res       Date:  2014-09-27

Review 5.  From obesity to diabetes and cancer: epidemiological links and role of therapies.

Authors:  Custodia García-Jiménez; María Gutiérrez-Salmerón; Ana Chocarro-Calvo; Jose Manuel García-Martinez; Angel Castaño; Antonio De la Vieja
Journal:  Br J Cancer       Date:  2016-02-23       Impact factor: 7.640

6.  Dose-Dependent Relationship Between Metformin and Colorectal Cancer Occurrence Among Patients with Type 2 Diabetes-A Nationwide Cohort Study.

Authors:  Yu-Tang Chang; Hsiang-Lin Tsai; Ya-Ting Kung; Yung-Sung Yeh; Ching-Wen Huang; Cheng-Jen Ma; Herng-Chia Chiu; Jaw-Yuan Wang
Journal:  Transl Oncol       Date:  2018-03-07       Impact factor: 4.243

Review 7.  2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications.

Authors:  Nieves González; Isabel Prieto; Laura Del Puerto-Nevado; Sergio Portal-Nuñez; Juan Antonio Ardura; Marta Corton; Beatriz Fernández-Fernández; Oscar Aguilera; Carmen Gomez-Guerrero; Sebastián Mas; Juan Antonio Moreno; Marta Ruiz-Ortega; Ana Belen Sanz; Maria Dolores Sanchez-Niño; Federico Rojo; Fernando Vivanco; Pedro Esbrit; Carmen Ayuso; Gloria Alvarez-Llamas; Jesús Egido; Jesús García-Foncillas; Alberto Ortiz
Journal:  Oncotarget       Date:  2017-03-14

Review 8.  High glucose: an emerging association between diabetes mellitus and cancer progression.

Authors:  Suangson Supabphol; Wunchana Seubwai; Sopit Wongkham; Charupong Saengboonmee
Journal:  J Mol Med (Berl)       Date:  2021-05-26       Impact factor: 4.599

9.  ZnCl2 sustains the adriamycin-induced cell death inhibited by high glucose.

Authors:  A Garufi; D Trisciuoglio; M Cirone; G D'Orazi
Journal:  Cell Death Dis       Date:  2016-06-30       Impact factor: 8.469

10.  p53-Dependent PUMA to DRAM antagonistic interplay as a key molecular switch in cell-fate decision in normal/high glucose conditions.

Authors:  Alessia Garufi; Giuseppa Pistritto; Silvia Baldari; Gabriele Toietta; Mara Cirone; Gabriella D'Orazi
Journal:  J Exp Clin Cancer Res       Date:  2017-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.